Inside Philip Morris’ controversial Vectura acquisition
The tobacco company’s buyout of a healthcare business has sparked both fury and confusion from campaigners and politicians.
By
Deals Analysis
Latest in
Deals Analysis
Science park merger creates UK’s largest life sciences ecosystem
Three companies have merged to form the UK’s first nationwide life sciences ecosystem, boosting R&D and drug discovery capacity in…
By
AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission review.
By
Exscientia raises $100m Series C funding to develop fully autonomous drug design
Exscientia has raised $100m in its second Series C in the past nine months. The round was led by BlackRock,…
By
SIRION and Sanofi partner on next-gen AAV gene therapy vectors
SIRION and Sanofi are partnering to develop improved AAV vectors to overcome some of the challenges facing gene therapies. The…
By
Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease
Merck has acquired Pandion Therapeutics for $1.85bn. The deal centres around Pandion’s TALON technology and immune modulators, which re-balance the…
By
Veteran investor Dr Robert Glassman talks life sciences, immunotherapy and Umoja
Immunotherapy-focused Umoja has appointed veteran investor Dr Robert Glassman to its board. Glassman discusses his extensive experience at Merrill Lynch,…
By
Targeting immune diseases: Longwood Fund founds ImmuneID with $17m financing
Longwood Fund has founded ImmuneID. The company focuses on developing precision medicines that target antibody interactions driving immune diseases using…
By